Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O2JI
|
|||
| Former ID |
DIB001398
|
|||
| Drug Name |
Ertumaxomab
|
|||
| Synonyms |
Rexomab; Rexomun; Trifunctional antibody (breast cancer), TRION/Fresenius; Trifunctional bispecific (CD3/Her2/neu) antibody (breast cancer), TRION/Fresenius
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1], [2] | |
| Company |
Trion
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22. | |||
| REF 2 | Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008 Oct;17(10):1553-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.